News
President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...
Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.
Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Pfizer will maintain its 2025 financial forecasts for now, but warned Tuesday it can’t predict the impact of any tariffs or trade policy changes ... production of small molecule drugs, ...
For perspective, the four drugs mentioned above account for about 10% of Pfizer's total top line. That's not even considering the potential added cost of drug ingredients needed to manufacture ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results